An NCI-designated Comprehensive Cancer Center, affiliated with the University of Pittsburgh School of Medicine
Research
We at UPMC Hillman Cancer Center are pleased to announce a new and exciting postdoctoral training opportunity. Made possible by a generous donation from Henry L. Hillman Foundation, the Hillman Postdoctoral Fellows for Innovative Cancer Research program seeks the nation’s…
Multiple classes of chemotherapeutic drugs work by inducing cancer cell death, but these drugs are often ineffective in treating cancer patients. Dr. Lin Zhang, Professor of Pharmacology and Chemical Biology, seeks to improve treatment outcome by studying the mechanisms underlying…
Basic and translational researchers at UPMC Hillman Cancer Center work closely with physician-scientists and clinicians to quickly move the most promising research results from their labs into clinical trials. While the conduct of clinical studies provides critical information to researchers…
On February 13, Pitt and UPMC leaders announced plans to establish the new UPMC Immune Transplant and Therapy Center (ITTC), with much of its activity planned within an eight-story innovation hub—all part of a concerted effort to harness the power…
Colorectal cancer (CRC) is a leading cause of cancer death in the United States and worldwide. While common oncogenic mutations in CRC have been identified, attempts to target these pathways have had limited success. Jian Yu, PhD, Professor of Pathology…
Tumors do not grow in isolation, but are surrounded by a rich microenvironment that contains blood vessels, fibroblasts, immune cells, and a multitude of other components. Cancer cells can influence their microenvironment through extracellular signaling mechanisms to enable and/or enhance…
While novel immunotherapies are revolutionizing the way some cancers are treated, not all patients will respond to treatment, underlining the need for biomarkers that can predict potential clinical benefit and monitor a patient’s response. Until recently, immune activity within and…
It is estimated that 40% of melanomas contain BRAF mutations that promote cancer cell growth. While previous studies have shown that treatment with the combination of inhibitors targeting BRAF (dabrafenib) and MEK (trametinib) improved survival in patients with advanced, unresectable…
Through Hillman Foundation and Henry L. Hillman Foundation, the late Henry and Elsie Hillman made generous contributions throughout the Pittsburgh region, especially in science and medicine. Their vision of making Pittsburgh a renowned leader in cancer care became a reality…
Last August, UPMC Hillman Cancer Center became one of only two academic centers in the nation to secure a competitive contract from the National Cancer Institute (NCI) to perform preclinical and clinical pharmacology research critical to the development of new…
